University of Michigan | Strategic Alliance Partners

Connect with us:

Latest from University of Michigan

ModraDoc006 Plus Ritonavir Shows Favorable Safety, Comparable Efficacy to IV Docetaxel in mCRPC

July 14, 2022

The combination of ModraDoc006—a novel, oral tablet formulation of docetaxel—and ritonavir produced comparable response rates and radiographic progression-free survival to that achieved with intravenous docetaxel in patients with metastatic castration-resistant prostate cancer.

Phillips Reflects on Lessons Learned With BTK Inhibitors in MCL

December 23, 2021

Dr Phillips discusses the utility of ibrutinib, acalabrutinib, and zanubrutinib in mantle cell lymphoma, the impact of long-term follow-up data with ibrutinib, and findings from the phase 3 SYMPATICO trial that could shake up the treatment paradigm.